Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 15/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 11/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.42 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485788 | 1.00 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5SGPL1 | |
| SCHEMBL2774941 | 1.00 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5SGPL1 | |
| SCHEMBL2485792 | 1.00 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5SGPL1 | |
| SCHEMBL2453805 | 0.85 | S1PR1 (0.37) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2453803 | 0.85 | S1PR1 (0.37) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2453802 | 0.85 | S1PR1 (0.37) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2778723 | 0.85 | KCNH2 (0.40) | S1PR3 | |
| SCHEMBL2777420 | 0.85 | KCNH2 (0.40) | S1PR3 | |
| SCHEMBL2777477 | 0.85 | KCNH2 (0.40) | S1PR3 | |
| SCHEMBL2446408 | 0.85 | KCNH2 (0.40) | S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | claimed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | claimed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | claimed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | claimed |
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2364088-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010051030-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | S1PR1 1/4885S1PR3 2/4885S1PR4 3/4885 |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.